News

Exciting Update on LOTIS-7 Clinical Trial by ADC Therapeutics

Exciting Update on LOTIS-7 Clinical Trial by ADC Therapeutics

Update on LOTIS-7 Clinical Trial from ADC Therapeutics

ADC Therapeutics SA (NYSE: ADCT), a pioneering leader in the field of antibody drug conjugates (ADCs), is preparing to share significant updates on its ongoing research concerning the LOTIS-7 Phase 1b clinical trial. This trial focuses on the efficacy and safety of ZYNLONTA in conjunction with the bispecific antibody glofitamab, specifically in patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

Upcoming Webcast Details

On a yet-to-be-specified Wednesday, ADC Therapeutics will conduct a conference call and a live webcast, offering insights into the latest findings from the LOTIS-7 trial. Participants are encouraged to dial in or join the webcast, which will begin promptly at 8:00 a.m. EST. Joining instructions and access information will be made available through the company's official investor relations page. For those unable to attend the live session, a recording will be accessible for 30 days post-event.

Understanding the LOTIS-7 Trial

The LOTIS-7 trial represents an important part of ADC Therapeutics' ongoing commitment to innovate in cancer treatment. The focus of this trial is on assessing ZYNLONTA, also known as loncastuximab tesirine-lpyl, which has shown promise for treating patients with specific types of lymphoma. This research is pivotal as it may offer new hope for individuals who have limited treatment options.

About ADC Therapeutics

ADC Therapeutics is dedicated to transforming patient care through its specialized portfolio of ADCs. Their lead product, ZYNLONTA, has been granted accelerated approval by the FDA, recognizing its potential to change the landscape of treatment for patients grappling with relapsed or refractory DLBCL. The company is also investigating other innovative approaches, including a next-generation PSMA-targeting ADC that integrates a novel payload approach featuring an exatecan-based compound linked with a unique hydrophilic connector.

Company Innovations and Developments

With headquarters in Lausanne, Switzerland, and with operations extending to London and New Jersey, ADC Therapeutics is focused on harnessing clinical and manufacturing advancements to facilitate innovation in ADCs. By continually enhancing their research efforts and expanding their product lines, they are stepping up to meet the challenges presented by complex oncological diseases.

The Future of ADC Therapeutics

The future looks bright for ADC Therapeutics as they leverage their unique technologies to potentially open up new therapeutic pathways for various forms of cancer. Their commitment to research and development ensures that they are not just keeping pace with the rapidly evolving landscape of oncology but also setting new benchmarks in patient care.

Contact ADC Therapeutics

For inquiries regarding ADC Therapeutics and their innovative therapies, investors and media representatives can reach out directly to the company. Nicole Riley, a key contact for communications, is available for further discussions, and the company offers robust channels for stakeholder engagement.

Frequently Asked Questions

What is the LOTIS-7 clinical trial about?

The LOTIS-7 trial investigates the safety and efficacy of ZYNLONTA combined with glofitamab in treating certain types of lymphoma.

When will the ADC Therapeutics update be available?

Details of the LOTIS-7 trial update will be shared during a webcast on a Wednesday at 8:00 a.m. EST.

What is ZYNLONTA?

ZYNLONTA, or loncastuximab tesirine-lpyl, is an ADC that has been approved for treating relapsed or refractory diffuse large B-cell lymphoma.

Where is ADC Therapeutics headquartered?

The company is headquartered in Lausanne, Switzerland, and operates globally.

How can I contact ADC Therapeutics for media inquiries?

For media inquiries, you can reach Nicole Riley at ADC Therapeutics, using the company’s provided contact channels.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

Updated Category News Views 24

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Continue Reading
Blokees Unveils 90+ New Wonders at Shanghai Fest

Updated Category News Views 17

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Updated Category News Views 20

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Continue Reading
SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Updated Category News Views 16

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Continue Reading
Lawsuit Highlights Inaction in School Bus Tragedy

Updated Category News Views 20

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Continue Reading
Black Culture Icon: Plastic-Covered Couch Takes Stage

Updated Category News Views 27

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris

Updated Category News Views 20

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness

Updated Category News Views 37

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence

Updated Category News Views 22

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Continue Reading
Class Action Alerts: M&A Under Scrutiny

Updated Category News Views 24

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Continue Reading

Top 5 Most Recently Viewed Articles

Potential Concerns for 23andMe Customers Amid Crisis

Updated Category News Views 110

23andMe's troubles began long before 2023, but now they’re hitting a crescendo that’s raising alarms among its customer base. The genetic testing giant, which once basked in a $6 billion valuation after its public debut in 2021, saw that figure crash to around $150 million. The implications for the estimated 15 million users relying on their services are huge—and...

Continue Reading
DNO ASA Boosts Dividends Following Significant Acquisition

Updated Category News Views 173

DNO ASA Reports Strong Second Quarter Performance DNO ASA, a Norwegian oil and gas operator, has shown impressive growth in its second quarter results. The company reported a substantial revenue increase of 37 percent, reaching USD 258 million from the previous quarter. The operating profit saw an even more remarkable rise of 206 percent, totaling USD 86 million. This...

Continue Reading
Terra Innovatum's Alliance with RAIT 88 for SOLO Reactor Expansion

Updated Category News Views 140

Strategic Partnership for Advanced Nuclear Technology Terra Innovatum Srl, a pioneering developer of micro-modular nuclear reactors, recently announced an exciting alliance with RAIT 88 Srl. This collaboration aims to accelerate the commercialization of its innovative SOLO™ Micro-Modular Reactor (MMR). RAIT 88 is recognized for its expertise in engineering, research and...

Continue Reading
LILYSILK's 15 Years of Transformative Growth and Vision

Updated Category News Views 140

Celebrating 15 Years of Innovation at LILYSILK LILYSILK, a revered name in the silk industry, proudly observes its 15th anniversary today. The celebration under the theme "From Little Threads to Big Dreams" is a testament to its remarkable journey. Since it began in 2010, this brand has transformed from a small startup into a global sensation known for its commitment to...

Continue Reading
Cheongju Craft Biennale 2025: A Landmark for Crafting Progress

Updated Category News Views 87

Celebrating the Success of Cheongju Craft Biennale 2025 The Cheongju Craft Biennale, an extraordinary celebration of creativity and craftsmanship, recently concluded its 2025 edition, signaling remarkable achievements for the event and the surrounding community. Impressive Attendance and Visitor Feedback Taking place in a vibrant atmosphere, this year's Biennale attracted...

Continue Reading